Neoadjuvant leukocyte interleukin injection immunotherapy improves overall survival in low-risk locally advanced head and neck squamous cell carcinoma –the IT-MATTERS study - Talor, Eyal; Tímár, József; Lavin, Philip; Cipriano, John; Markovic, Dusan; Ladányi, Andrea; Karpenko, Andrey; Bondarenko, Igor; Stosic, Srboljub; Sobat, Hrvoje; Zhukavets, Aliaksandr; Imamovic, Nazim; et al. (Pathology oncology research, 2025)
Keywords: Adult; Aged; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - therapy; Female; Follow-Up Studies; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - mortality; Head and Neck Neoplasms - pathology; Head and Neck Neoplasms - therapy; Humans; immunotherapy; Immunotherapy - methods; Immunotherapy - mortality; Interleukins - administration & dosage; Interleukins - therapeutic use; Leukocyte interleukin injection (LI); locally advanced disease; low-risk for recurrence; Male; Middle Aged; neoadjuvant; Neoadjuvant Therapy - methods; Neoadjuvant Therapy - mortality; Prognosis; SCCHN; Squamous Cell Carcinoma of Head and Neck - drug therapy; Squamous Cell Carcinoma of Head and Neck - mortality; Squamous Cell Carcinoma of Head and Neck - pathology; Squamous Cell Carcinoma of Head and Neck - therapy; Survival Rate; low-risk for recurrence; neoadjuvant; immunotherapy; lower disease burden; SCCHN; Leukocyte interleukin injection (LI); locally advanced disease